Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease

Azacitidine (Aza) is first-line treatment for patients with high-risk myelodysplastic syndromes (MDS), although its precise mechanism of action is unknown. We performed the first study to globally evaluate the epigenetic effects of Aza on MDS bone marrow progenitor cells assessing gene expression (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobiasson, Magnus, Abdulkadir, Hani, Lennartsson, Andreas, Katayama, Shintaro, Marabita, Francesco, Paepe, Ayla De, Karimi, Mohsen, Krjutskov, Kaarel, Einarsdottir, Elisabet, Grövdal, Michael, Jansson, Monika, Azenkoud, Asmaa Ben, Corddedu, Lina, Lehmann, Sören, Ekwall, Karl, Kere, Juha, Hellström-Lindberg, Eva, Ungerstedt, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438694/
https://www.ncbi.nlm.nih.gov/pubmed/28427179
http://dx.doi.org/10.18632/oncotarget.15807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438694/
https://www.ncbi.nlm.nih.gov/pubmed/28427179
http://dx.doi.org/10.18632/oncotarget.15807

Ejemplares similares